




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61N 1/30		A1	(11) International Publication Number: WO 97/49450 (43) International Publication Date: 31 December 1997 (31.12.97)
(21) International Application Number: PCT/US97/10975		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 23 June 1997 (23.06.97)		Published <i>With international search report.</i> <i>With amended claims.</i>	
(30) Priority Data: 08/668,725 24 June 1996 (24.06.96)		US	
(71) Applicant: GENETRONICS, INC. [US/US]; 11199-A Sorrento Valley Road, San Diego, CA 92121-1334 (US).			
(72) Inventors: DEV, Sukhendu, B.; 5205 Fiore Terrace #B-215, San Diego, CA 92122 (US). DEV, Nagendu, B.; 2065 Random #6, Cleveland, OH 44106 (US). HOFMANN, Gunter, A.; 3750 Riviera Drive #6, San Diego, CA 92109 (US).			
(74) Agent: HAILE, Lisa, A.; Fish & Richardson P.C., Suite 1400, 4225 Executive Square, La Jolla, CA 92037 (US).			

(54) Title: ELECTROPORATION-MEDIATED INTRAVASCULAR DELIVERY

ENDOLUMINAL ELECTROPORATION CATHETER



(57) Abstract

A method for sustained intravascular delivery via electroporation is provided. The method is useful for delivery of therapeutic compositions such as antithrombotic and anticoagulant agents. The invention also provides a catheter apparatus for introducing a composition into at least one cell in a vessel in a subject.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ELECTROPORATION-MEDIATED INTRAVASCULAR DELIVERY5 Field of the Invention

The present invention relates generally to the field of electroporation and specifically to a method of sustained intravascular delivery of compositions such as antithrombotic and anticoagulant agents.

10 Background of the Invention

For some time now, it has been known that electric fields could be used to create pores in cells without causing permanent damage to them. This discovery made possible the insertion of large molecules into cell 15 cytoplasm. It is known that genes and other molecules such as pharmacological compounds can be incorporated into live cells through a process known as electroporation.

Treatment of cells by electroporation is carried 20 out by infusing a composition into a patient and applying an electric field to the desired site of treatment between a pair of electrodes. The field strength must be adjusted reasonably accurately so that electroporation of the cells occurs without damage, or at least minimal 25 damage, to any normal or healthy cells. The distance between the electrodes can then be measured and a suitable voltage according to the formula $E=V/d$ can then be applied to the electrodes (E=electric field strength in V/cm; V=voltage in volts; and d=distance in cm).

30 Studies have also shown that large size nucleotide sequences (up to 630 kb) can be introduced into mammalian

- 2 -

cells via electroporation (Eanault, et al., *Gene (Amsterdam)*, 144(2):205, 1994; *Nucleic Acids Research*, 15(3):1311, 1987; Knutson, et al., *Anal. Biochem.*, 164:44, 1987; Gibson, et al., *EMBO J.*, 6(8):2457, 1987; 5 Dower, et al., *Genetic Engineering*, 12:275, 1990; Mozo, et al., *Plant Molecular Biology*, 16:917, 1991), thereby affording an efficient method of gene therapy, for example.

Iontophoresis uses electrical current to activate 10 and to modulate the diffusion of a charged molecule across a biological membrane, such as the skin, in a manner similar to passive diffusion under a concentration gradient, but at a facilitated rate. In general, 15 iontophoresis technology uses an electrical potential or current across a semipermeable barrier. Delivery of heparin molecules to patients has been shown using iontophoresis (IO), a technique which uses low current (d.c.) to drive charged species into the arterial wall. Iontophoretic delivery of heparin (1000U/ml) into porcine 20 artery was shown to be safe and well tolerated without any change in the coronary angiography or normal physiological parameters such as blood pressure and cardiac rhythm. Although heparin in varying concentration from 1000 U to 20,000 U/ml results in greater 25 concentrations remaining in the vessel after IO delivery compared to passive delivery, approximately 1 hour after the delivery of heparin, 96% of the drug washes out (Mitchel, et al., ACC 44th Annual Scientific Session, Abs.#092684, 1994). It has also been reported that 30 platelet deposition following IO delivery of heparin is reduced in the pig balloon injury model. ^{125}I -labeled hirudin has also been delivered iontophoretically into porcine carotid artery (Fernandez-Ortiz, et al.,

- 3 -

Circulation, 89:1518, 1994). A local concentration of hirudin can be achieved by IO, however, as with the above experiments with heparin, 80% of the drug washes out in 1 hour and after three hours, the level is the same as for 5 the passive delivery.

Heparins are widely used therapeutically to prevent and treat venous thrombosis. Apart from interactions with plasma components such as antithrombin III or heparin cofactor II, interactions with blood and 10 vascular wall cells may underlie their therapeutic action. The term heparin encompasses to a family of unbranched polysaccharide species consisting of alternating 1-4 linked residues of uronic acid (L-iduronic or D-glucuronic) and D-glucosamine. Crude 15 heparin fractions commonly prepared from bovine and porcine sources are heterogeneous in size (5,000-40,000 daltons), monosaccharide sequence, sulfate position, and anticoagulant activity. Mammalian heparin is synthesized by connective tissue mast cells and stored in granules 20 that can be released to the extracellular space following activation of these cells. Overall, heparin is less abundant than related sulfated polysaccharides, such as heparan sulfate, dermatan sulfate, and chondroitin sulfate, which are synthesized in nearly all tissues of 25 vertebrates. Heparin and these other structures are commonly referred to as glycosaminoglycans.

The anticoagulant activity of heparin derives primarily from a specific pentasaccharide sequence present in about one third of commercial heparin chains 30 purified from porcine intestinal mucosa. This pentasaccharide, $-\alpha\text{GlcNR16S}\beta(1-4)\text{GlcA}\alpha(1-4)\text{GlcNS3S6R2}\alpha(1-4)\text{IdoA2S}\alpha(1-4)\text{GlcNS6S}$ where R1 = $-\text{SO}_3^-$ or $-\text{COCH}_3$, and R2 = $-\text{H}$ or $-\text{SO}_3^-$, is a high affinity ligand for the circulating

- 4 -

plasma protein, antithrombin (antithrombin III, AT-III), and upon binding induces a conformational change that results in significant enhancement of antithrombin's ability to bind and inactivate coagulation factors, 5 thrombin, Xa, IXa, VIIa, XIa and XIIa. For heparin to promote antithrombin's activity against thrombin, it must contain the specifically recognized pentasaccharide and be at least 18 saccharide units in length. This ~~and~~ additional length is believed to be necessary in order to 10 bridge antithrombin and thrombin, thereby optimizing their interaction. Other polymers found in heparin have platelet inhibitory effects or fibrinolytic effects. In clinical development are the low molecular weight heparins (LMW). The heparin compounds contain only the 15 specific polymers required for antithrombin III activation. They have greater specific antithrombotic activity and less antiplatelet activity. They also have the characteristic of being easier to dose and being safer.

20 A major objective of many biotechnology companies and pharmaceutical industries is to find safe, easy and effective ways of delivering drugs and genes. Specifically, in the area of cardiology, there has been tremendous interest in the delivery of drugs and genes 25 into the arterial wall by a variety of means. Brief reviews have appeared on gene transfer methods related to cardiology (Dzau, et al., *TIBTECH*, 11:205, 1993; Nabel, et al., *TCM*, Jan.-Feb. issue:12, 1991). On the viral front, retroviruses, despite their high efficiency of 30 transfer, have various limitations, such as 1) size (<8 kb), 2) potential for activation of oncogenes, 3) random integration and, 4) inability to transfect non-dividing cells. Other viral vectors such as adenovirus are

- 5 -

efficient but have the potential risk of infection and inflammation. HVJ-mediated transfection, although highly efficient, can exhibit non-specific binding. Liposomes, which have become very popular, are safe and easy to work with, but have low efficiency and long incubation times. 5 Recent changes in the formulation of liposomes have, however, has increased their efficiency several fold.

~~Catheter delivery systems, with many different catheter balloon configurations, have also been used to locally~~
10 deliver genes and/or drugs. These include: hydrogel balloon, laser-perforated (Wolinsky balloon), 'weeping,' channel and 'Dispatch' balloons and variations thereof (Azrin, et al., *Circulation*, 90:433, 1994; Consigny, et al., *J. Vasc. Interv. Radiol.*, 5:553, 1994; Wolinsky, et 15 al., *JACC*, 17:174B, 1991; Riessen, et al., *JACC*, 23:1234, 1994; Schwartz, Restenosis Summit VII, Cleveland, OH, 1995, pp 290-294). Delivery capacity with hydrogel balloon is limited and, during placement, the catheter can lose substantial amount of the drug or agent to be 20 introduced. High pressure jet effect in Wolinsky balloon can cause vessel injury which can be avoided by making many holes, <1 μ m, (weeping type). The 'Dispatch' catheter has generated a great deal of interest for drug delivery and it create circular channels and can be used as a 25 perfusion device allowing continuous blood flow.

Gene transfer to endothelium and vascular smooth muscle cells, and site-specific gene expression by retrovirus and liposome have been shown feasible, and cell seeding of vascular prosthesis and stents have also 30 been described (Nabel, et al., *JACC*, 17:189B, 1991; Nabel et al., *Science*, 249:1285, 1990). An ideal method of gene delivery would be intracellular introduction of nucleic

- 6 -

acid sequences (e.g., plasmid DNA), locally, to give high level gene expression over a reasonable period of time.

Summary of the Invention

The present invention provides a method for local 5 and sustained intravascular delivery of a composition in a subject by pulsed electric field, or electroporation. The mode of delivery described herein allows retention of the composition in a vessel in the subject for an extended period of time. The method is a catheter-based 10 system for delivery of therapeutic agents, for example, directly into the cells of the vessel wall. Sustained, high local concentrations of a composition is achieved using the method of the invention.

The method of the invention is useful for 15 intravascular delivery of such compositions as antiproliferative, anticoagulative, antithrombotic, antirestenoitic and antiplatelet agents. The method is useful for cardiologic applications such as treatment of deep-vein thrombosis (DVT), unblocking clogged carotid 20 arteries, peripheral arterial disease and cardiovascular restenosis, for example.

The invention also provides a catheter apparatus for introducing a composition into at least one cell in a vessel in a subject.

25

Brief Description of the Drawings

Figure 1 is a schematic illustration of an endoluminal catheter.

Figure 2, top, shows a computer image of 30 fluoresceinated heparin in the pulsed rabbit artery, and bottom, in the non-pulsed artery.

- 7 -

Figure 3 shows confocal microscopy images of rabbit arteries after fluoresceinated heparin treatment. R1L1 shows the left artery, no pulse; R1R1 shows the right artery, with pulse; R2L1 shows the left artery, 5 with pulse; and R2E1 shows the right artery, no pulse.

Figure 4 shows confocal microscopy fluorescent images of rabbit arteries after heparin treatment. 4L2 shows left artery with pulse; 4R2 shows right artery no pulse; 4L1 shows left artery with pulse; and 1L3 shows 10 left artery no pulse.

Figure 5 shows confocal microscopy fluorescent images of rabbit arteries after heparin treatment. 12R1, right artery with pulse and 12L1, left artery, no pulse.

Figure 6 is a schematic diagram of a rabbit 15 treated by the method of the invention, including the catheter description.

Figure 7 is a schematic diagram of an exemplary endoluminal electroporation catheter of the invention.

Figure 8, panels a-c, show x-rays of insertion of 20 the catheter into the carotid artery (a), infusion of radiocontrast dye (b), and balloon inflation (c), respectively.

Description of the Preferred Embodiments

The present invention provides a method for the 25 local, controlled, and sustained intravascular delivery of a therapeutic composition to a vessel in a subject using electroporation techniques. The method utilizes pulsed electric fields and has an advantage of allowing lower concentrations of compositions to be utilized as 30 opposed to high dosages typically used with passive delivery modalities.

- 8 -

The method of the invention provides a delivery system that allows controlled sustained, high local concentrations of pharmacologic agents to be delivered directly at a site without exposing the entire 5 circulation to the agent. Pharmacologic approaches to inhibit smooth muscle cells migration and proliferation, for example, have been effectively used at supraphysiological doses in animal research studies. However, such high concentrations may be impractical for 10 clinical use in humans because of the risk of systemic side effects and the lack of specific targeting of drugs given systemically at such high dosages. This invention is clinically relevant for the local treatment of arteries undergoing catheter-based interventions, such as 15 angioplasty, atherectomy, rotablasting or stenting, for example.

In a preferred embodiment, the invention provides a method for sustained intravascular delivery of a composition to a subject. The method includes 20 administering the composition to the subject and applying an electrical impulse to a vessel via electroporation, wherein the impulse is of sufficient strength and time for the impulse to cause electroporation of at least one cell in the interior of the vessel such that the 25 composition is delivered into the cells in the vessel and is retained in the vessel thereby resulting in sustained delivery. In one aspect of the invention, iontophoresis can be employed to further deliver the composition to a cell, either prior to, simultaneously with or after 30 electroporation.

The term "sustained" as used herein means that once the composition is delivered to the vessel, it is retained in the vessel for a period of time of as long as

- 9 -

24 to about 36 hours, and typically for 12 hours. In other words, there is no appreciable washout of the composition as compared with the concentration of the composition delivered under conventional delivery (e.g., 5 passive diffusion or IO) .

The terms "intravascular" and "vessel" mean any artery, vein or other "lumen" in the subject's body to which the electric pulse can be applied and in which the composition can be delivered. A lumen is known in the art 10 as a channel within a tube or tubular organ. Examples of preferred vessels in the method of the invention include the coronary artery, carotid artery, the femoral artery, and the iliac artery. While not wanting to be bound by a particular theory, it is believed that the electric 15 impulse applied to the vessel allows the delivery of the composition primarily to the cells of the medial region of the vessel, but also to the intima and less so to the adventitia.

The composition delivered by the method of the 20 invention includes any composition which would have a desired biological effect at the site of electroporation. For example, preferred compositions include antithrombotic, antirestenoitic, antiplatelet, and antiproliferative compositions. Other compositions 25 include platelet receptor and mediator inhibitors, smooth muscle cell proliferation inhibitors, growth factor inhibitors, GpIIb/IIIa antagonists, agents that inhibit cell adhesion and aggregation, agents that block thromboxane receptors, agents that block the fibrinogen 30 receptor, etc. Specific examples of such compositions include heparin (including high and low molecular weight and fragments thereof), hirulog, tissue plasminogen activator (tPA), urokinase, streptokinase, warfarin,

- 10 -

hirudin, angiotensin converting enzyme (ACE) inhibitors, PDGF-antibodies, proteases such as elastase and collagenase, serotonin, prostaglandins, vasoconstrictors, vasodialators, angiogenesis factors, Factor VIII or 5 Factor IX, TNF, tissue factor, VLA-4, growth-arrest homeobox gene, gax, L-arginine, GR32191, sulotroban, ketanserin, fish oil, enoxaprin, cilazapril, forinopril, lovastatin, angiopeptin, cyclosporin A, steroids, trapidil, colchicine, DMSO, retinoids, thrombin 10 inhibitors, antibodies to von Willebrand factor, antibodies to glycoprotein IIb/IIIa, calcium chelation agents, etc. Other therapeutic agents (e.g., those used in gene therapy, chemotherapeutic agents, nucleic acids (e.g., polynucleotides including antisense, for example 15 c-myc and c-myb), peptides and polypeptides, including antibodies) may also be administered by the method of the invention.

The therapeutic composition can be administered alone or in combination with each other or with another 20 agent. Such agents include combinations of tPA, urokinase, prourokinase, heparin, and streptokinase, for example. Administration of heparin with tissue plasminogen activator would reduce the dose of tissue plasminogen activator that would be required, thereby 25 reducing the risk of clot formation which is often associated with the conclusion of tissue plasminogen activator and other thrombolytic or fibrinolytic therapies.

Compositions used in the method of the invention 30 include biologically functional analogues of the compositions described herein. For example, such modifications include addition or removal of sulfate groups, addition of phosphate groups and addition of

- 11 -

hydrophobic groups such as aliphatic or aromatic aglycones. Modifications of heparin, for example, include the addition of non-heparin saccharide residues such as sialic acid, galactose, fucose, glucose, and 5 xylose. When heparin is used as the composition, it may include a fragment of naturally occurring heparin or heparin-like molecule such as heparan sulfate or other glycosaminoglycans, or may be synthetic fragments. The synthetic fragments could be modified in saccharide 10 linkage in order to produce more effective blockers of selectin binding. Methods for producing such saccharides will be known by those of skill in the art (see for example: M. Petitou, Chemical Synthesis of Heparin, in Heparin, Chemical and Biological Properties, Clinical 15 Applications, 1989, CRC Press Boca Raton, FL, D.A. Lane and V. Lindahl, eds. pp. 65-79).

The composition administered by the method of the invention may be a mixture of one or more compositions, e.g., heparin and tPA. Further, compositions such as 20 heparin may include a mixture of molecules containing from about 2 to about 50 saccharide units or may be homogeneous fragments as long as the number of saccharide units is 2 or more, but not greater than about 50.

Where a disorder is associated with the expression of a gene (e.g., IGF-1, endothelial cell growth factor), nucleic acid sequences that interfere with the gene's expression at the translational level can be delivered. This approach utilizes, for example, antisense nucleic acid, ribozymes, or triplex agents to 25 block transcription or translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or triplex agent, or by cleaving it with a ribozyme. 30

- 12 -

Preferably the subject is a human, however, it is envisioned that the method of sustained *in vivo* delivery of compositions via electroporation as described herein can be performed on any animal.

5 Preferably, the therapeutic composition is administered either prior to or substantially contemporaneously with the electroporation treatment. The term "substantially contemporaneously" means that the ~~substantially~~ therapeutic composition and the electroporation treatment 10 are administered reasonably close together with respect to time. The chemical composition of the agent will dictate the most appropriate time to administer the agent in relation to the administration of the electric pulse. The composition can be administered at any interval, 15 depending upon such factors, for example, as the nature of the clinical situation, the condition of the patient, the size and chemical characteristics of the composition and half-life of the composition.

The composition administered in the method of the 20 invention can be administered parenterally by injection or by gradual perfusion over time. The composition can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally, and preferably is administered 25 intravascularly at or near the site of electroporation.

Preparations for administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils 30 such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Vehicles include

- 13 -

sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those 5 based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases, and the like. Further, vasoconstrictor agents can be used to keep the therapeutic composition 10 localized prior to pulsing.

In another embodiment, the invention provides a catheter device 100 useful in the method of the invention that can be modified as described herein, as shown in Figures 1, 6, and 7. The catheter may be, for example, a 15 modified Berman catheter (Arrow International, Inc., Reading, PA). One of skill in the art will know of other balloon catheter devices for endoluminal electroporation mediated drug delivery that can be modified according to the present invention.

20 The catheter 100 may include at least one inflatable balloon 102 near the distal end of the catheter 100, and at least one inflation port 104 for inflating each balloon 102, in a conventional manner. The catheter 100 also includes a first electrode 110 and a 25 second electrode 112 that are coupled by wires to a voltage source generator 114, which may be, for example, an ECM 600 exponential generator from BTX, a division of Genetronics, Inc., San Diego, California. The first electrode 110 is preferably placed close to at least one 30 infusion opening 120. In one embodiment, the infusion openings 120 may be coincident with the first electrode 110, such that the first electrode 110 completely surrounds at least one infusion opening 120.

- 14 -

The first electrode 110 is preferably made of an electrically conductive material that is biologically compatible, e.g., biologically inert, with a subject. Examples of such material include silver or platinum wire 5 wrapped around or laid on or near the surface of the catheter 100; a plated or painted coating of conductive material, such as silver paint, on some portion of the catheter 100; or a region of the catheter 100 that has been made conductive by implantation (during or after 10 manufacture, such as by ion implantation) of electrically conductive materials, such as powdered metal or conductive fibers. The conductor need not be limited to metal, but can be a semiconductor or conductive plastic or ceramic. For ease of manufacture, the embodiments 15 illustrated in Figures 6 and 7 use conductive silver paint for the first electrode 110 as a coating on approximately 2.5 cm of the length of the catheter 100 near the infusion ports 120.

The second electrode 112 similarly comprises an 20 electrically conductive material, and can be of the same or different type of conductive material as the first electrode 110. In the embodiment shown in Figure 6, the second electrode comprises a silver plate 112a configured to be applied to a portion of the body of a subject such 25 that an electric field sufficient to cause electroporation of at least one cell in a vessel is generated when voltage from the voltage source 114 is applied to the first electrode 110 and the second electrode 112. The second electrode, when placed 30 externally, is preferably placed on bare skin (e.g., shaved abdominal muscle of the subject), preferably using a conductive gel for better contact. Figure 7 shows that

- 15 -

the second electrode 112 may be a conductive guide wire for the catheter 100.

The first electrode 110 and the second electrode 112 are coupled to the voltage source 114 by conductors, 5 which may be, for example, silver or platinum wires, but can be any conductive structure, such as flexible conductive ink within the catheter 100 for connecting the first electrode 110.

The infusion ports 120 can be made during or after 10 manufacture of the catheter 100, and can be placed on one or both sides of the first electrode 110, or within the bounds of the first electrode 110.

In an alternative embodiment, the second electrode 112 may be formed in a manner similar to the first 15 electrode 110 and positioned between the first electrode 110 and the infusion openings 120, or positioned with the infusion openings 120 between the first electrode 110 and the second electrode 112. Other configurations of the first electrode 110 and the second electrode 112 can be 20 utilized, such as interdigitated electrodes with infusion openings 120 nearby or between the interdigitated "fingers" of the electrodes, or as concentric rings with the infusion openings within the centermost ring, between the centermost and outermost ring, and/or outside of the 25 outermost ring. Additional configurations are within the scope of the present invention so long as they provide a structure that, when supplied by voltage from the voltage source 114, generates an electric field sufficient to cause electroporation of at least one cell in the vessel.

30 In operation, the catheter 100 is positioned so that a balloon 102 traverses or crosses a stenotic lesion, for example, and the balloon 102 is inflated to expand the vessel (e.g., an artery or vein), thereby

- 16 -

dilating the lumen of the vessel. A therapeutic composition is delivered into the vessel via the infusion openings 120, and at least during part of the time before, during, or after infusion occurs, electrical 5 pulses from the voltage source 114 are applied to the first electrode 110 and second electrode 112 so as to cause electroporation of at least one cell in the vessel. Following delivery of the therapeutic composition to such cell, the catheter may be withdrawn, unless additional 10 composition delivery and electroporation is desired.

The methods described above are also applicable with metallic stents. The stent itself forms one set of electrodes while a guide wire acts as the second electrode. Stents, on their own, or coated with heparin, 15 are useful for reduction of restenosis. Such results can be further augmented when combined with pulsed electric fields. This would be particularly suitable for angioplasty where a stent is deployed. (For detailed review, see de Jaegere, P.P. et al., *Restenosis Summit* 20 *Proc. VIII*, 1996, pp82-109). Stent implantation, along with local delivery of antirestenotic drugs by pulsed electric fields reduces the restenosis rate. Besides a normal stent, a retractable or biodegradable stent can also be used with this mode of delivery.

25 In another aspect of the invention, the described method is useful for bypass grafts. These can include aortocoronary, aortoiliac, aortorenal, femoropopliteal. In the case of a graft with autologous or heterologous tissue, the cells in the tissue can be electroporated, ex 30 vivo, with a nucleic acid encoding a protein of interest. Since electroporation is relatively fast, a desired nucleic acid can be transferred in a saphenous vein, e.g., outside the body, while the extracorporeal

- 17 -

circulation in the patient is maintained by a heart-lung machine, and the vein subsequently grafted by standard methods. Where synthetic material is used as a graft, it can serve as a scaffolding where appropriate cells 5 containing a nucleic acid sequence of interest that has been electroporated, *ex vivo*, can be seeded.

The method of the invention can be used to treat ~~disorders by delivery of any composition, e.g., drug or~~ gene with a catheter, as described herein. For example, 10 patients with peripheral arterial disease, e.g., critical limb ischemia (Isner, J.M. et al, Restenosis SummitVIII, Cleveland, OH, 1996, pp 208-289) can be treated as described herein. Both viral and non-viral means of gene delivery can be achieved using the method of the 15 invention. These include delivery of naked DNA, DNA-liposome complex, ultraviolet inactivated HVJ (haematoagglutinating virus of Japan) liposome vector, delivery by particle gun (e.g., biolistics) where the DNA is coated to inert beads, etc. Various nucleic acid 20 sequences encoding a protein of interest can be used for treatment of cardiovascular disorders, for example. The expression of the growth factors PDGF-B, FGF-1 and TGF β 1 has been associated with intimal hyperplasia, therefore, it may be desirable to either elevate (deliver sense 25 constructs) or decrease (deliver antisense) such gene expression. For example, whereas PDGF-B is associated with smooth muscle cell (SMC) proliferation and migration, FGF-1 stimulates angiogenesis and TGF β 1 accelerates procollagen synthesis.

30 Any composition that inhibits SMC proliferation and migration, platelet aggregation and extracellular modeling is also desirable for use in the electroporation-mediated delivery method of the

- 18 -

invention. Such compositions include interferon- γ which inhibits proliferation and expression of α -smooth muscle actin in arterial SMCs and non-protein mediators such as prostaglandin of the E series.

5 Examples of other genes to be delivered by the method of the invention includes Vascular endothelial growth factor (VEGF) and endothelial specific mitogen, which can stimulate angiogenesis and regulate both physiologic and pathologic angiogenesis.

10 Administration of the composition in the method of the invention may be used for ameliorating post-reperfusion injury, for example. When treating arterial thrombosis, induction of reperfusion by clot lysing agents such as tissue plasminogen activator (tPA) is 15 often associated with tissue damage.

Administration of the composition by the method of the invention, alone or in combination with other compositions, for example that may be administered passively, is useful in various clinical situations.

20 These include but are not limited to: 1) acute arterial thrombotic occlusion including coronary, cerebral or peripheral arteries; 2) acute thrombotic occlusion or restenosis after angioplasty; 3) reocclusion or restenosis after thrombolytic therapy (e.g., in an 25 ischemic tissue); 4) vascular graft occlusion; 5) hemodialysis; 6) cardiopulmonary bypass surgery; 7) left ventricular cardiac assist device; 8) total artificial heart and left ventricular assist devices; 9) septic shock; and 10) other arterial thromboses (e.g., 30 thrombosis or thromboembolism where current therapeutic measures are either contraindicated or not effective).

The method of the invention is also useful for the treatment of microbial infections. Many microbes, such

- 19 -

as bacteria, rickettsia, various parasites, and viruses, bind to vascular endothelium and leukocytes. Thus, the method of the invention may be used to administer a composition to a patient to prevent binding of a microbe 5 which uses a particular receptor (e.g., selectin) as its binding target molecule, thereby modulating the course of the microbial infection.

The method of the invention can be used to treat vasculitis by administering to a patient a composition 10 described above. Tissue damage associated with focal adhesion of leukocytes to the endothelial lining of blood vessels is inhibited by blocking the P- and L-selectin receptors, for example.

The dosage ranges for the administration of the 15 compositions in the method of the invention are those large enough to produce the desired effect in which the symptoms of the disease/injury are ameliorated. The dosage should not be so large as to cause adverse side effects. Generally, the dosage will vary with the age, 20 condition, sex and extent of the disease in the patient and can be determined by one of skill in the art. The dosage can be adjusted by the individual physician in the event of any complication. When used for the treatment of inflammation, post-reperfusion injury, microbial/viral 25 infection, or vasculitis, or inhibition of the metastatic spread of tumor cells, for example, the therapeutic composition may be administered at a dosage which can vary from about 1 mg/kg to about 1000 mg/kg, preferably about 1 mg/kg to about 50 mg/kg, in one or more dose 30 administrations.

Controlled delivery may be achieved by selecting appropriate macromolecules, for example, polyesters, polyamino acids, polyvinyl pyrrolidone, ethylene-

- 20 -

vinylacetate, methylcellulose, carboxymethylcellulose, protamine sulfate, or lactide/glycolide copolymers. The rate of release of the therapeutic composition may be controlled by altering the concentration of the 5 macromolecule.

Another method for controlling the duration of action comprises incorporating the composition into particles of a polymeric substance such as polyesters, polyamino acids, hydrogels, polylactide/glycolide 10 copolymers, or ethylenevinylacetate copolymers.

Alternatively, it is possible to entrap the composition in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, by the use of hydroxymethylcellulose or gelatin- 15 microcapsules or poly(methylmethacrylate) microcapsules, respectively, or in a colloid drug delivery system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, 20 mixed micelles, and liposomes.

The various parameters including electric field strengths required for the electroporation of any known cell is generally available from the many research papers reporting on the subject, as well as from a database 25 maintained by Genetronics, Inc., San Diego, California, assignee of the subject application. The electric fields needed for *in vivo* cell electroporation are similar in amplitude to the fields required for cells *in vitro*. These are in the range of from 100 V/cm to several kV/cm. 30 This has been verified by the inventors own experiments and those of others reported in scientific publications.

Pulse generators for carrying out the procedures described herein are and have been available on the

- 21 -

market for a number of years. One suitable signal generator is the ELECTRO CELL MANIPULATOR Model ECM 600 commercially available from BTX, a division of Genetronics, Inc., of San Diego, California, U.S.A. The 5 ECM 600 signal generator generates a pulse from the complete discharge of a capacitor which results in an exponentially decaying waveform. The electric signal generated by this signal generator is characterized by a fast rise time and an exponential tail. In the ECM 600 10 signal generator, the electroporation pulse length is set by selecting one of ten timing resistors marked R1 through R10. They are active in both High Voltage Mode (HVM) (capacitance fixed at fifty microfarads) and Low Voltage Mode (LVM) (with a capacitance range from 25 to 15 3,175 microfarads).

The application of an electrical field across the cell membrane results in the creation of transient pores which are critical to the electroporation process. The ECM 600 signal generator provides the voltage (in kV) that 20 travels across the gap (in cm) between the electrodes. This potential difference defines what is called the electric field strength where E equals kV/cm . Each cell has its own critical field strength for optimum 25 electroporation. This is due to cell size, membrane make-up and individual characteristics of the cell wall itself. For example, mammalian cells typically require between 0.5 and 5.0 kV/cm before cell death and/or electroporation occurs. Generally, the required field strength varies inversely with the size of the cell.

30 The ECM 600 signal generator has a control knob that permits the adjustment of the amplitude of the set charging voltage applied to the internal capacitors from 50 to 500 volts in LVM and from 0.05 to 2.5kV in the HVM.

- 22 -

The maximum amplitude of the electrical signal is shown on a display incorporated into the ECM 600 signal generator. This device further includes a plurality of push button switches for controlling pulse length, in the 5 LVM mode, by a simultaneous combination of resistors parallel to the output and a bank of seven selectable additive capacitors.

The ECM 600 signal generator also includes a single automatic charge and pulse push button. This 10 button may be depressed to initiate both charging of the internal capacitors to the set voltage and to deliver a pulse to the outside electrodes in an automatic cycle that takes less than five seconds. The manual button may be sequentially pressed to repeatedly apply the 15 predetermined electric field.

The waveforms of the voltage pulse provided by the generator in the power pack can be an exponentially decaying pulse, a square pulse, a unipolar oscillating pulse train or a bipolar oscillating pulse train, for 20 example. Preferably, the waveform used for the method of the invention is an exponential pulse. The voltage applied between the at least first and second electrode is sufficient to cause electroporation of the vessel such the composition delivered to the vessel is retained for a 25 period of time, as described above. The field strength is calculated by dividing the voltage by the distance (calculated for 1 cm separation; expressed in cm) between the electrodes. For example, if the voltage is 500 V between two electrode faces which is 1/2 cm apart, then 30 the field strength is $500/(1/2)$ or 1000 V/cm or 1 kV/cm. Preferably, the amount of voltage applied between the electrodes is in the range of about 10 volts to 200 volts, and preferably from about 50 to 90 volts.

- 23 -

The pulse length can be 100 microseconds (μ s) to 100 millisecond (ms) and preferably from about 500 μ s to 10 ms. There can be from about 1 to 10 pulses applied to an area or group of cells. The waveform, electric field strength and pulse duration are dependent upon the exact construction of the catheter device and types of molecules in the composition to be transferred to the ~~surrounding~~ ~~cells or vessel~~ via electroporation. One of skill in the art would readily be able to determine the appropriate pulse length and number of pulses.

The following examples are intended to illustrate but not limit the invention. While they are typical of those that might be used, other procedures known to those skilled in the art may alternatively be used.

15

EXAMPLE 1

ENDOLUMINAL INJECTION OF FLUORESCEINATED HEPARIN AND PULSED ELECTRICAL STIMULATION OF THE CAROTID ARTERY IN A SPONTANEOUSLY BREATHING RABBIT

1. Methods

20 Experiments were performed in 12 New Zealand white rabbits of either sex (2.5 - 3.4 kg) preanesthetized with xylazine (2mg. \cdot kg $^{-1}$) and ketamine (50mg. \cdot kg $^{-1}$) intramuscularly and an injection of alphachloralose (30 mg. \cdot kg $^{-1}$) intraveneously through an ear vein. A 25 supplemental dose of 10mg. \cdot kg $^{-1}$ chloralose was given every hour. The anesthetic state was maintained such that the toe-pinch reflex and corneal reflexes were absent.

All experiments were conducted in accordance with the guidelines adopted by American Physiological Society 30 on the use of animals for research.

- 24 -

Animals were placed supine and strapped on the surgical table. The trachea was intubated to allow spontaneous breathing of ambient air. Electrocardiogram (EKG) of the animal was obtained by using Lead II in 5 differential mode. End-tidal CO₂ tension was monitored by a CO₂ analyzer (Datex, Puritan-Bennett). Body temperature was kept at the 38-38.5°C range by radiant heating.

2. Surgical preparation and experimental protocol.

A longitudinal incision in the cervical region was 10 made in the rabbit to expose the common carotid arteries on both sides. Approximately 6cm in length of carotid artery on each side was isolated from the surrounding tissue and vago sympathetic nerve trunk. The caudal end of the carotid artery on one side was transiently occluded 15 with a vascular clip at the junction between the neck and chest. A small incision was then made at the rostral end of the artery (just below transversus vein) to push an electroporator catheter (Figure 1) through this incision. After insertion of the catheter, the catheter balloon was 20 repeatedly inflated for 30 seconds inside the arterial lumen in order to denude the endothelial lining. An indelible ink mark was placed on the inflated portion of the artery. The balloon was then deflated and the catheter tip was held just above the vascular clip.

25 A 0.2ml of freshly prepared diluted heparin (1 mg. of fluoresceinated heparin (F-heparin) with an activity of 167 unit/mg [Molecular Probe, Inc.] dissolved in 4 ml) was injected through the one port of a double lumen catheter over a period of about 10 seconds. The catheter 30 was then pulled out of the artery and the vascular clip was taken off from the caudal end to restore blood flow in the artery. Exactly the same procedure was adopted for

- 25 -

the contralateral carotid artery (test artery). The only exception was that for the test artery, the carotid artery was stimulated intraluminally using a platinum or silver electrode. Two platinum or silver wires were 5 coiled around the catheter just above the balloon for a length of about 10 mm with an interelectrode distance of 2mm-3mm.

Lead II EKG was differentially amplified and the output was continuously monitored on an oscilloscope 10 (Tektronix) and recorded on a Gould TA-2000 thermal-array recorder for evaluation. 1-12 hours after heparin injection, both carotid arteries were excised and immediately flash frozen in isopentane pre-chilled in liquid nitrogen. Arteries were stored in -70°C until 15 further processing.

Arterial segments were subsequently freeze sectioned (10 micron) transversely. Microscopic slides containing arterial sections were observed under a Zeiss confocal laser (argon-krypton) scan microscope (LSM 410 20 Invert), (excitation at 495 nm and emission at 515 nm) to obtain video image (magnification 40 times) of fluorescence. Subsequently, control and test samples were compared by analyzing fluorescence intensity by Line 25 Intensity Scan at different depths of the arterial wall using commercially obtained software (Image 1:Universal Imaging Corp.).

3. Protocols of Pulsed Stimulation

The luminal wall of the carotid artery was stimulated through bipolar platinum or silver electrodes, 30 which were laid against the luminal surface sufficiently without damage. Pulsed activation of the luminal surface was obtained using an exponential pulse generator (Model

- 26 -

ECM 600, BTX, a division of Genetronics, Inc., San Diego, CA). Four pulses of 50-60 V amplitude with a pulse width of ~500 μ s were applied over a period of 60 seconds. This protocol was adopted either for the left or right carotid 5 artery.

4. Observation and Data Analysis.

During pulse stimulation of the carotid artery, mild twitching of the cervical region could be seen, but no appreciable change was observed in EKG dynamics over 10 the entire experimental duration.

Green fluorescence heparin of the arterial wall could be distinctly seen in the microscopic slide preparations (in different layers of the arterial wall). Confocal scan image of the arterial wall showed 15 penetration of F-heparin in both control and test samples. However, it was evident that the fluorescent-intensity in the test sample was much stronger and went into the deeper region of the arterial wall (Figures 2-5).

20 The pulsed electrical stimulation facilitated introduction of small amount (~50 ug) of F-heparin effectively to the deeper region of arterial wall in a physiologically normal experimental animal. Heparin was mostly present in the media but also in the intima of the 25 vessel wall. However, the intensity dropped significantly towards the adventitia. It is possible that only the portion of the electrode making contact with the luminal wall shows more fluorescence than the adjacent space. From the tissue sectioning, it is not possible to say 30 which portion of the tissue sectioning of the luminal wall sample had contact with the electrodes. However, it is possible that if some sections in the test sample show

- 27 -

greater penetration and intensity than the others, those sections probably were in contact with the luminal wall. Also, the fluorescent image could not ascertain if balloon inflation of the bilateral arteries had equal 5 degree of endothelial denudation, the variation in which could alter the penetration of F-heparin among the samples.

Figure 1 shows a schematic of the catheter used in the above examples. One of the problems of working with 10 fluoresceinated heparin is that there is considerable amount of autofluorescence from the collagen and elastin of the tissue sample. In absolute terms of fluorescent intensity, these tend to distort the real pattern of the fluorescence in the vessel wall due to heparin alone. 15 However, in the present examples, in every case, it is clear that the relative fluorescent intensity was always stronger in the treated vessel that was pulsed compared to the non-pulsed artery. All the photographs had identical magnification (40X) and the brightness and 20 contrast were set to the same level for photography (Figures 2-5). All epifluorescence images were monitored in Sony videocon monitor attached to a Hamamatsu CCD camera.

However, by processing the samples at higher pH 25 (9.0), it was possible to considerably reduce or even eliminate the interfering autofluorescence. The photos of Figures 2-5 indicated that the local delivery of heparin in the vessel completely washes out in two hours, whereas heparin delivery in the pulsed artery was sustained for 30 at least 12 hours.

EXAMPLE 2

Figure 6 shows another configuration for a catheter useful in the method of the invention, whereby conductive silver paint or a similar conductive material 5 is placed around the catheter covering a length of approximately 2.5 cm. This portion of the catheter is attached to a silver wire which, in turn, is connected to one terminal of a generator, e.g., ECM 600 exponential generator (BTX, a division of Genetronics, Inc., San 10 Diego, CA). The second electrode is placed externally and is placed on the abdominal muscle, preferably using a gel for better contact (Figure 6, shaved area). This second electrode, serving as the anode, is in turn connected to the other terminal of the generator.

15 Another embodiment of the catheter comprises one electrode positioned between two balloons and a guidewire acting as a second catheter. Such a configuration is shown in Figure 7. This catheter was used in the following experiment. Three rabbits weighing ~4Kg were 20 anesthetized with xylazine (0.1 ml/kg) and ketamine (0.5 ml/kg i.m.). General anesthesia was maintained with α -chloralose (30 mg/Kg. i.v.). Intubation was endotracheal, as described in example 1. A femoral artery in the leg on one side of the rabbit was exposed. 25 A 5F sheath was introduced and the catheter was pushed under fluoroscopic guidance to the right or left carotid artery. A series of x-rays, Figure 8, panels a-c, show successful deployment of the catheter (panel a, insertion). Radiocontrast fluid was infused (panel b) 30 allowing confirmation of the catheter position, the patient artery, the balloon and the built-in radiopaque marker, as well as presence of the dye in the side branches. After balloon inflation, (panel c) 1 ml of

- 29 -

fluoresceinated heparin (concentration 1 mg dissolved in 2 ml: biological activity of heparin as per manufacturer: 167 U) was infused between the occluded segment via the drug port and the artery pulsed immediately with the 5 balloons in the inflated condition. Initially, field parameters tested were ~60V and four pulses each of ~600 μ s pulse length. With these settings, very little uptake of heparin was observed in the treated artery. In a subsequent experiment, voltage and pulse length were 10 changed to 57V and 22 ms, respectively. As before, four pulses were delivered from ECM 600 pulse exponential generator. The balloon was deflated immediately afterwards with the catheter taken out, but the sheath was left behind to avoid bleeding from the nicked femoral 15 artery. Two hours after infusion of F-heparin, both arteries (treated and the contralateral untreated artery) were taken out for processing. Microscopic images of the treated artery showed massive uptake of the heparin. The fluorescent image of the artery was extremely 20 intense, and the separated arterial sections could not be discerned. Although the control artery also shows fluorescence, visually it was much weaker. Although heparin was not delivered into the control artery, it is obvious that there was systemic circulation from infusion 25 of heparin in the treated artery- part of which must have been taken up by the control artery. In addition, fluorescence due to collagen and elastin was also present. However, both autofluorescence correction at higher pH, as described previously, and computer 30 subtraction of the fluorescence from the control artery from that of the treated artery, showed deep penetration and uptake of the F-heparin in the pulsed artery.

- 30 -

A similar catheter (as depicted in Figure 7) was also used for a gene marking experiment in a rabbit carotid artery. A New Zealand white rabbit weighing 3.5Kg was anesthetized with ketamine/xylene cocktail 5 (IM). Intubation was with halothane @ 1%. After a midline incision, the right common carotid was isolated with silk ligature. 5F sheath was placed into right common carotid over the guidewire after an initial scissor nick in artery. 014" Schneider guidewire was placed through the 10 sheath into the left iliac artery. The electroporation (EP) catheter was advanced over the wire to left iliac artery. 50% contrast injections with the balloon inflated through the infusion port guided placement to avoid side branches. The infusion sleeve was flushed with saline and 15 the balloons inflated 2 atom. Plasmid (150 μ l) (a standard marker gene, lacZ, driven by a CMV promoter) was injected into the infusion port followed by saline. The iliac was pulsed from a BTX ECM 600 exponential pulse generator. Three pulses were given at approximately 10 20 sec intervals at 76 V and 758 μ s.

For the control artery, balloons were deflated and the wire placed down the right iliac. The procedure was as described above, except that no pulse was applied. The dwell time was -30 secs. After the procedure, the 25 balloons were deflated and catheters and wires removed. The carotid was ligated proximal and distal to the entry site and the incision was closed in 2 layers. 1500 units of heparin were given after the sheath was in place.

The plasmid DNA was electroporated into the rabbit 30 iliac artery (catheter was guided through to the iliac via the carotid as described above) and gene expression was confirmed five days later using standard x-gal

- 31 -

processing of the artery. In contrast, the control artery did not show detectable gene expression.

EXAMPLE 3

For further drug delivery studies, the same 5 protocol will be followed as described in detail in Example 1. Forty New Zealand white rabbits will be used for these studies. Time points of approximately 2 hours and 24 hours (group 1) will be tested with balloon catheters as described herein.

10 Twenty animals, ten animals in each of the time points of group 1, will be used. Both the left and the right arteries will serve as the treated (T) and the control (C). These will be chosen randomly but the number for the T and C will be the same. An ECM 600 pulse 15 generator, which delivers exponential pulses and was used to generate the results described above, will also be used for these experiments.

Ten animals will be tested with square wave pulses from a BTX T820 Square Wave Pulser and arteries will be 20 excised after two hours for subsequent studies. The arteries which will serve as T and C will be randomized. BTX T820 delivers square wave pulses where the number of pulses, the voltage and the pulse length can be adjusted. The voltage is about 60V and the pulse parameters are: 25 four pulses delivered at 1 Hz each of 40 ms (based on studies with the BTX T820 on rat vascular smooth muscle cell experiments *in vitro*). Square wave pulses have been known to be gentler to some cells. In this group, there will be five arteries in each of the treated and control 30 category. The inflammatory response of the vessel due to balloon inflation as well as application of the pulsed electric field is also evaluated.

- 32 -

Twenty rabbits will be used where the catheter will be introduced either percutaneously or via a small incision in the femoral. This would give results on twenty treated and twenty control arteries. Arteries will 5 be processed after eight hours. The ECM 600 will be used to deliver exponential pulses. An endoluminal balloon catheter used herein has one electrode between two balloons whereas the guide wire will serve as the second electrode (one design). To facilitate proper viewing of 10 the balloons in the inflated and the deflated position under fluoroscopic guidance, radio-opaque markers will be put in appropriate positions. Calculations suggest that there will be enough field penetration into the arteries to deliver drugs although the electrodes are not in 15 direct contact with the arteries.

For each of the specific aims given above, electric field plots will be generated using a commercially available software package EMP (Field Precision, Albuquerque, New Mexico). This package solves 20 Poisson's equation is solved numerically by finite elements methods. The initial parameters are electrode geometry, resistivities of the artery from the lumen side and the connective tissue side and the range of field strength to be investigated.

25 The amount of heparin left in the vessel will be determined in each case following a procedure recommended by Molecular Probe. An InSpeck Microscope Image Intensity Calibration Kit will be used. First, the microscope will be calibrated with the beads 30 (microsphere) provided in the kit and the fluorescein-heparin solution will be equilibrated to the 100% microsphere. Alternatively, for different size

- 33 -

microsphere, the available figures for "fluorescein equivalent per microsphere" can be used.

The protocol for reduction of autofluorescence due to collagen and elastin from the arterial wall of the 5 isolated rabbit carotid artery is as follows: Tris-buffered glycerol is prepared (90 ml glycerol and 5 ml of 0.5M Tris-HCl, pH 9.0). This is dispensed in 19 ml aliquots in glass scintillation vials and stored 4°C 2% n-propyl gallate (npg: anti-fading substance) is prepared 10 in tris-buffer (2 mg npg and 1.0 ml of 0.5M tris-HCl, pH 9.0) is prepared fresh and protected from light. 1 ml of the 2% npg solution is added to 19 ml of tris-buffered glycerol and the solution is protected from light. This is the solution used to mount arterial sections on to the 15 microscopic glass slides. Precaution needs to be taken that the solution is discarded on discoloration. All images will be obtained at 40X magnification under immersion oil (Plan-Neofluor objective). Identical brightness and contrast will be set for all photographs.

20 Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the 25 following claims.

What is claimed is:

1. A method for sustained intravascular delivery of a composition to a vessel in a subject, the method comprising:
 - 5 administering the composition to the subject;
 - applying an electrical impulse to a vessel via electroporation, wherein the impulse is of sufficient strength and time for the impulse to cause electroporation of at least one cell in the
 - 10 interior of the vessel such that the composition is delivered into the vessel and is retained in the vessel for sustained delivery.
2. The method of claim 1, wherein the composition is administered systemically or locally.
- 15 3. The method of claim 1, wherein the composition is selected from the group consisting of an antithrombotic, antirestenoitic, antiplatelet, platelet receptor and mediator inhibitor, growth factor inhibitor, antibody, antiinflammatory and
- 20 antiproliferative composition.
4. The method of claim 3, wherein the composition is selected from the group consisting of heparin, hirulog, tPA, urokinase, streptokinase, cyclosporin, antistatin, and warfarin.
- 25 5. The method of claim 1, wherein the electrical impulse applied is from approximately 50 to 90 volts.

- 35 -

6. The method of claim 1, wherein the electrical impulse applied has a duration of about 100 μ s to 100 ms.
7. The method of claim 6, wherein the electrical impulse applied has a duration of from about 100 μ s to 1000 μ s.
8. The method of claim 1, wherein the administering of the composition and the application of the electrical impulse are substantially contemporaneous.
9. The method of claim 1, wherein application of the electrical impulse is via a catheter apparatus.
10. The method of claim 1, wherein the electrical impulse(s) is comprised of square wave pulses, exponential waves, unipolar oscillating wave forms of limited duration, bipolar oscillating wave forms of limited duration, or other wave forms generating electric fields.
11. The method of claim 1, wherein the electrical impulse(s) is comprised of square wave or exponential wave pulses.
12. The method of claim 1, wherein the electrical impulse has a pulsing frequency of about 1 to 100 Hz.
- 25 13. The method of claim 1, wherein from about 1 to 10 electrical pulses are applied.

- 36 -

14. The method of claim 1, further comprising using iontophoresis for delivery of the composition to the cell.

15. The method of claim 1, wherein the vessel is a
5 blood vessel.

16. An apparatus for introducing a composition into at least one cell in a vessel in a subject comprising:

10 a catheter having at least one inflatable balloon portion;
at least one infusion passage for introducing the composition into the subject;
a first electrode positioned adjacent to at least one infusion passage;
15 a second electrode positioned with respect to the first electrode and the subject such that an electric field sufficient to cause electroporation of at least one cell in the vessel is generated, thereby allowing the composition to enter at least one cell after introduction of the composition through at
20 least one infusion passage.

17. The apparatus of claim 16, further comprising an electrical source connected to the first and
25 second electrodes for applying a voltage between the electrodes in an amount sufficient to cause electroporation of at least one cell.

18. The apparatus of claim 16, wherein the vessel is a blood vessel.

- 37 -

19. The apparatus of claim 16, wherein the first electrode is formed at least in part by a biologically inert material.
20. The apparatus of claim 16, wherein the second electrode is a guidewire in the catheter.
21. The apparatus of claim 16, wherein the second electrode is a silver plate configured to be placed in contact with the subject.

AMENDED CLAIMS

[received by the International Bureau on 27 October 1997 (27.10.97);
original claim 11 cancelled; original claims 1,4,10 and 17-21 amended;
claims 12-21 renumbered as claims 11-20; remaining claims unchanged
(4 pages)]

1. A method for sustained intravascular delivery of a composition to cells of a vessel in a subject, the method comprising:
 - 5 administering the composition to the subject;
 - applying an electrical impulse to cells of a vessel in the subject via electroporation, at random time intervals, wherein the impulse is of sufficient strength and time for the impulse to cause electroporation of at least one cell in the interior of the vessel such that the composition is delivered into the vessel and is retained in the vessel for sustained delivery .
- 10 2. The method of claim 1, wherein the composition is administered systemically or locally.
- 15 3. The method of claim 1, wherein the composition is selected from the group consisting of an antithrombotic, antirestenoitic, antiplatelet, platelet receptor and mediator inhibitor, growth factor inhibitor, antibody, antiinflammatory and antiproliferative composition.
- 20 4. The method of claim 3, wherein the composition is heparin, hirulog, tPA, urokinase, streptokinase, cyclosporin, antistatin, or warfarin.
- 25 5. The method of claim 1, wherein the electrical impulse applied is from approximately 50 to 90 volts.


6. The method of claim 1, wherein the electrical impulse applied has a duration of about 100 μ s to 100 ms.
7. The method of claim 6, wherein the electrical impulse applied has a duration of from about 100 μ s to 1000 μ s.
8. The method of claim 1, wherein the administering of the composition and the application of the electrical impulse are substantially contemporaneous.
9. The method of claim 1, wherein application of the electrical impulse is via a catheter apparatus.
10. The method of claim 1, wherein the electrical impulse(s) is selected from the group consisting of square wave pulses, exponential waves, unipolar oscillating wave forms of limited duration, bipolar oscillating wave forms of limited duration, and other wave forms generating electric fields.
11. The method of claim 1, wherein the electrical impulse has a pulsing frequency of about 1 to 100 Hz.
12. The method of claim 1, wherein from about 1 to 10 electrical pulses are applied.

13. The method of claim 1, further comprising using iontophoresis for delivery of the composition to the cell.
14. The method of claim 1, wherein the vessel is a blood vessel.
15. An apparatus for introducing a composition into at least one cell in a vessel in a subject comprising:
 - 10 a catheter having at least one inflatable balloon portion;
 - 15 at least one infusion passage for introducing the composition into the subject;
 - 20 a first electrode positioned adjacent to at least one infusion passage;
 - 25 a second electrode positioned with respect to the first electrode and the subject such that an electric field sufficient to cause electroporation of at least one cell in the vessel is generated, thereby allowing the composition to enter at least one cell after introduction of the composition through at least one infusion passage.
16. The apparatus of claim 15, further comprising an electrical source connected to the first and second electrodes for applying a voltage between the electrodes in an amount sufficient to cause electroporation of at least one cell.
17. The apparatus of claim 15, wherein the vessel is a blood vessel.

18. The apparatus of claim 15, wherein the first electrode is formed at least in part by a biologically inert material.
19. The apparatus of claim 15, wherein the second electrode is a guidewire in the catheter.
20. The apparatus of claim 15, wherein the second electrode is a silver plate configured to be placed in contact with the subject.

1/9



FIGURE 1




ENDOLUMINAL CATHETER FOR ELECTROPORATION - MEDIATED DRUG DELIVERY

2/9

FIG. 2




3/9



- PZL1: Heparin, no pulse (left artery)
- PZL2: Heparin, with pulse (right artery)
- PZR1: Heparin, with pulse (left artery)
- PZR2: Heparin, without pulse (right artery)

4/9




411: Regardin - pulse (left artery)

412: Regardin, no pulse (right artery)

413: Regardin - pulse (left artery)


414: Regardin, no pulse (left artery)

5/9



12.1 Heparin - pulse right artery
12.1 Heparin, no pulse left artery

METHOD (SUPINE POSITION)




UNIPOLAR ELECTRODE ARRANGEMENT

FIGURE 6

7/9

FIGURE 7
ENDOLUMINAL ELECTROPOORATION CATHETER



8/9




Figure 8a

9/9




Figure 8b




Figure 9c

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/10975

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61N 1/30

US CL : 604/21, 49

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 604/19-21, 49

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,019,034 A (WEAVER et al.) 28 May 1991, col. 9; col. 4, line 15; and col. 11, line 14.	1, 2, 5-8, 10-13, 15
X — P	US 5,634,899 A (SHAPLAND et al.) 03 June 1997, cols. 4-6, 9 and 10.	1, 2, 5-12, 14-19
Y		3, 4, 21
Y	US 5,498,238 A (SHAPLAND et al.) 12 March 1996, col. 6, lines 20-38.	3, 4
X — P	US 5,554,119 A (HARRISON et al.) 10 September 1996, col. 21, lines 27-55.	16-19
Y		20, 21

 Further documents are listed in the continuation of Box C.

See patent family annex.

Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"		document defining the general state of the art which is not considered to be of particular relevance
"B"		earlier document published on or after the international filing date
"L"		document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"		document referring to an oral disclosure, use, exhibition or other means
"P"		document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search

12 AUGUST 1997

Date of mailing of the international search report

29 AUG 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ELLEN TAO

Telephone No. (703) 308-2108

Form PCT/ISA/210 (second sheet)(July 1992)★

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/10975

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4,747,819 A (PHIPPS et al.) 31 May 1988, col. 5.	21
Y	US 5,425,703 A (FEIRING) 20 June 1995, cols. 5 and 6, lines 1-67.	21
A	US 5,088,977 A (SIBALIS) 18 February 1992, col. 4, lines 15-28.	3, 4

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/10975

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS

Search Terms: guide wire, electrode, silver, 604/21, square wave, exponential wave, unipolar oscillating wave form, bipolar oscillating wave form, electrophor?